Edition:
United States

Camurus AB (CAMX.ST)

CAMX.ST on Stockholm Stock Exchange

129.75SEK
15 Dec 2017
Change (% chg)

0.25kr (+0.19%)
Prev Close
129.50kr
Open
130.00kr
Day's High
130.00kr
Day's Low
128.25kr
Volume
19,219
Avg. Vol
29,146
52-wk High
145.75kr
52-wk Low
103.00kr

Chart for

About

Camurus AB is a Sweden-based research and development based pharmaceutical company with a focus on the development and commercialization of specialty medicines, providing patients suffering from serious and chronic disease, such as opioid dependence, pain, cancer, acromegaly, and neuroendocrine tumors. The Company has a... (more)

Overall

Beta: --
Market Cap(Mil.): kr4,837.27
Shares Outstanding(Mil.): 37.28
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.20 16.04
EPS (TTM): -- -- --
ROI: -- 15.06 34.69
ROE: -- 16.55 15.46

BRIEF-Camurus Q3 operating loss widens to SEK ‍67.1​ million

* Q3 NET REVENUE SEK ‍12.5​ MILLION VERSUS SEK 30.5 MILLION YEAR AGO

Oct 26 2017

BRIEF-Camurus and Braeburn announce submission of NDA for long-acting buprenorphine (CAM2038) for opioid use disorder

* CAMURUS AND BRAEBURN ANNOUNCE SUBMISSION OF NDA FOR LONG-ACTING BUPRENORPHINE (CAM2038) FOR OPIOID USE DISORDER

Jul 20 2017

BRIEF-Camurus Q2 operating loss widens to SEK ‍58.7​ mln

* Q2 REVENUE SEK ‍19.1​ MILLION VERSUS SEK 25.8 MILLION YEAR AGO

Jul 13 2017

BRIEF-Camurus and Braeburn Pharma announce phase 2 results for long-acting Buprenorphine in opioid dependent patients with chronic pain

* Camurus and Braeburn Pharmaceuticals announce topline phase 2 results for long-acting buprenorphine in opioid dependent patients with chronic pain

Jul 12 2017

BRIEF-Trial results suggest that Camurus' CAM2038 formulations would be effective in reducing illicit opioid use, relapse

* LONG-ACTING BUPRENORPHINE BLOCKS OPIOID EFFECTS AND SUPPRESSES WITHDRAWAL SYMPTOMS IN ADULTS WITH OPIOID USE DISORDER

Jun 22 2017

Earnings vs. Estimates